Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breakthrough brain cancer trial tests targeted drug duos

NCT ID NCT04446962

Ongoing Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding either lenalidomide or ibrutinib to standard chemotherapy works better for adults with newly diagnosed primary brain lymphoma. The first part determines safe drug doses, while the second part compares how well patients respond to each combination. Patients who respond well will proceed to stem cell transplant as part of their treatment plan.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CH Colmar

    Colmar, France

  • CH côte Basque

    Bayonne, 64100, France

  • CHRU Lille

    Lille, 69000, France

  • CHU Amiens

    Amiens, France

  • CHU Angers

    Angers, France

  • CHU Besançon

    Besançon, France

  • CHU Caen

    Caen, France

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU Créteil

    Créteil, France

  • CHU Dijon

    Dijon, France

  • CHU Grenoble

    Grenoble, France

  • CHU La Timone Marseille

    Marseille, France

  • CHU Limoges

    Limoges, France

  • CHU Lyon

    Lyon, France

  • CHU Nancy

    Nancy, France

  • CHU Nantes

    Nantes, France

  • CHU Nîmes - Carémeau

    Nîmes, 30029, France

  • CHU Pitié-Salpêtrière

    Paris, 75013, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rennes

    Rennes, 35000, France

  • CHU Strasbourg-Hôpital Hautepierre

    Strasbourg, 67098, France

  • CHU Tours

    Tours, France

  • Centre Henri Becquerel

    Rouen, 76000, France

  • Centre Lacassagne

    Nice, France

  • Hôpital Cochin

    Paris, 75006, France

  • IUCT -Oncopole

    Toulouse, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Curie

    Paris, 75005, France

Conditions

Explore the condition pages connected to this study.

CENTRAL NERVOUS SYSTEM NEOPLASMS, PRIMARY LYMPHOMA, LARGE B-CELL, DIFFUSE